Selexipag is associate oral medication known as a prostacyclin informatics receptor agonist indicated for the treatment of pulmonic blood vessel cardiovascular disease (PAH, UN agency cluster one PH) in UN agency purposeful category II and III patients, to delay unwellness progression and scale back the chance of hospitalization for PAH.
Selexipag (brand name Uptravi) may be a drug developed by Actelion for the treatment of pulmonic blood vessel cardiovascular disease (PAH). Selexipag and its active matter, square measure agonists of the prostacyclin receptor, that ends up in dilatation within the circulation.
The adverse effects of selexipag square measure just like those of blood vessel prostacyclins used for pulmonic blood vessel cardiovascular disease. Common aspect effects embrace headache and jaw pain. associate redoubled risk for gland disease has additionally been noted in folks taking selexipag.
